Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
400 studies found for:    "Abdominal Neoplasms"
Show Display Options
Rank Status Study
1 Completed Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Conditions: Abdominal Neoplasms;   Pelvic Neoplasms
Intervention: Drug: Optison
2 Recruiting Nutritional Supplementation in Patients With no Signs of Malnutrition
Conditions: Primary Neoplasm;   Secondary Neoplasm;   Abdominal Neoplasm
Intervention: Dietary Supplement: Nutritional supplements
3 Completed
Has Results
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Conditions: Abdominal Neoplasm;   Colonic Neoplasm;   Mesothelioma;   Peritoneal Neoplasm
Interventions: Procedure: Surgery;   Procedure: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin;   Drug: Postoperative dwell with paclitaxel and 5-FU
4 Completed Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
Condition: Abdominal Neoplasms
Interventions: Drug: enoxaparin;   Other: Physical prophylaxis
5 Completed Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer
Conditions: Surgery;   Perioperative Care;   Immunization;   Abdominal Neoplasms
Interventions: Behavioral: perioperative fluid management;   Behavioral: perioperative fluid treatment
6 Unknown  Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients
Conditions: Abdominal Tumor;   Intestinal Obstruction;   Cirrhosis;   Intestinal Fistula;   Aneurism
Interventions: Drug: dexmedetomidine;   Drug: propofol
7 Recruiting TAP Versus Thoracic Epidural in Major Abdominal Resections
Conditions: Malignant Neoplasm of Abdomen;   Surgery
Interventions: Drug: Exparel 1.33% (20ml Volume);   Drug: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
8 Recruiting Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
Conditions: Cancer of Kidney and Renal Pelvis;   Cancer of Liver
Intervention: Drug: Dexmedetomidine
9 Unknown  Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Procedure: disease screening;   Procedure: evaluation of cancer risk factors;   Procedure: genitourinary surgical procedure;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
10 Terminated Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Intervention:
11 Completed UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: 7-hydroxystaurosporine;   Drug: topotecan hydrochloride
12 Recruiting Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tubes Cancer;   Peritoneal Cancer
Interventions: Procedure: Secondary Cytoreductive Surgery;   Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC);   Drug: platinum-based systemic chemotherapy postoperatively
13 Withdrawn Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine;   Drug: IDO1 inhibitor INCB024360;   Other: laboratory biomarker analysis;   Other: pharmacological study
14 Completed Combination Chemotherapy Plus Erlotinib in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
15 Completed Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: pemetrexed disodium
16 Recruiting Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions: Anxiety Disorder;   Fallopian Tube Cancer;   Fatigue;   Nausea and Vomiting;   Neurotoxicity;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
17 Recruiting Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery by laparoscopy
18 Active, not recruiting Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Conditions: Genital Diseases, Female;   Ovarian Diseases;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Interventions: Biological: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: specialized pathology review (Germany only)
19 Terminated A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
Condition: Ovarian, Fallopian or Primary Peritoneal Cancer.
Intervention: Drug: Alemtuzumab
20 Completed ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: plevitrexed;   Drug: topotecan hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years